Related Experiment Videos
Molecular and biologic characterization of recombinant interferon-alpha2b
R Bordens1, S E Grossberg, P P Trotta
1Schering-Plough Research Institute, Kenilworth, NJ 07033, USA.
Seminars in Oncology
|June 1, 1997
Summary
Recombinant interferon-alpha2b (IFN-alpha2b) is a highly purified therapeutic protein. Developed tests confirm its consistent quality and low incidence of antibody formation in patients, ensuring safe and effective cancer and hepatitis treatment.
Area of Science:
- Biotechnology
- Pharmaceutical Science
- Immunology
Background:
- Recombinant interferon-alpha2b (IFN-alpha2b) is an approved therapy for cancers and chronic hepatitis B and C.
- The production of highly purified IFN-alpha2b requires robust characterization methods.
Purpose of the Study:
- To describe purity and identity tests for physicochemical properties and bioactivity of highly purified IFN-alpha2b.
- To evaluate the consistency of production and assess antibody formation in patients.
Main Methods:
- Characterization of IFN-alpha2b using physicochemical and bioactivity assays.
- Antiviral bioassay using FS-71 cells to measure potency against encephalomyocarditis virus.
- Immunoassays to quantify binding and neutralizing antibodies in treated patients.
Main Results:
- Highly purified IFN-alpha2b (2.5 x 10(8) IU/mg protein) can be consistently produced without DNA contamination.
- The antiviral bioassay effectively measures IFN-alpha2b potency.
- A very low incidence of neutralizing antibody formation was observed in patients.
Conclusions:
- The developed tests ensure the consistent production of high-purity IFN-alpha2b.
- IFN-alpha2b therapy is associated with a low risk of neutralizing antibody development.
- Recommendations for IFN reference standards and antibody neutralization titer calculations are provided.